Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 2
1937 2
1945 1
1946 5
1947 6
1949 3
1950 2
1951 1
1952 4
1953 2
1954 3
1955 1
1956 2
1957 5
1958 1
1959 2
1964 1
1965 1
1966 3
1970 3
1971 1
1972 2
1975 1
1983 1
2009 1
2010 1
2011 1
2012 2
2013 1
2014 2
2015 11
2016 6
2017 6
2018 11
2019 9
2020 17
2021 38
2022 15
Text availability
Article attribute
Article type
Publication date

Search Results

159 results
Results by year
Filters applied: . Clear all
Page 1
Antimicrobial Resistance in ESKAPE Pathogens.
De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ. De Oliveira DMP, et al. Among authors: harris pna. Clin Microbiol Rev. 2020 May 13;33(3):e00181-19. doi: 10.1128/CMR.00181-19. Print 2020 Jun 17. Clin Microbiol Rev. 2020. PMID: 32404435 Free PMC article. Review.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Harris PNA, et al. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2).
Stewart AG, Paterson DL, Young B, Lye DC, Davis JS, Schneider K, Yilmaz M, Dinleyici R, Runnegar N, Henderson A, Archuleta S, Kalimuddin S, Forde BM, Chatfield MD, Bauer MJ, Lipman J, Harris-Brown T, Harris PNA; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Stewart AG, et al. Among authors: harris pna. Open Forum Infect Dis. 2021 Aug 2;8(8):ofab387. doi: 10.1093/ofid/ofab387. eCollection 2021 Aug. Open Forum Infect Dis. 2021. PMID: 34395716 Free PMC article.
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP, Lin RTP, Chew KL, Yin M, Lee TH, Yilmaz M, Cakmak R, Alenazi TH, Arabi YM, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj SS, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke DFM, Runnegar NJ, Miyakis S, Walls G, Khamis MAI, Zikri A, Crowe A, Ingram PR, Daneman N, Griffin P, Athan E, Roberts L, Beatson SA, Peleg AY, Cottrell K, Bauer MJ, Tan E, Chaw K, Nimmo GR, Harris-Brown T, Harris PNA; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Henderson A, et al. Among authors: harris pna. Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850. doi: 10.1093/cid/ciaa1479. Clin Infect Dis. 2021. PMID: 33106863 Clinical Trial.
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG, Harris PNA, Chatfield MD, Littleford R, Paterson DL. Stewart AG, et al. Among authors: harris pna. Trials. 2021 Apr 22;22(1):301. doi: 10.1186/s13063-021-05206-8. Trials. 2021. PMID: 33888139 Free PMC article. Clinical Trial.
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. Harris PN, et al. Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9. Trials. 2015. PMID: 25623485 Free PMC article. Clinical Trial.
Reply to Rezahosseini and Nielsen.
McNamara JF, Harris PNA, Chatfield MD, Paterson DL. McNamara JF, et al. Among authors: harris pna. Clin Infect Dis. 2021 Jun 1;72(11):e916. doi: 10.1093/cid/ciaa1449. Clin Infect Dis. 2021. PMID: 32970797 No abstract available.
Melioidosis, Singapore, 2003-2014.
Pang L, Harris PNA, Seiler RL, Ooi PL, Cutter J, Goh KT, Cook AR, Fisher D, Chai LYA. Pang L, et al. Among authors: harris pna. Emerg Infect Dis. 2018 Jan;24(1):140-3. doi: 10.3201/eid2401.161449. Emerg Infect Dis. 2018. PMID: 29260679 Free PMC article.
Health Risks of Flood Disasters.
Paterson DL, Wright H, Harris PNA. Paterson DL, et al. Among authors: harris pna. Clin Infect Dis. 2018 Oct 15;67(9):1450-1454. doi: 10.1093/cid/ciy227. Clin Infect Dis. 2018. PMID: 30986298 Review.
159 results